Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Portfolio Pulse from Vandana Singh
Sandoz AG has settled its patent litigation with Amgen Inc over the bone disorder drug denosumab, allowing for the launch of biosimilars Jubbonti and Wyost by May 31, 2025. The settlement will not affect Sandoz's 2024 guidance, and these biosimilars have received FDA approval. Amgen's Prolia, a reference medicine for these biosimilars, received a serious warning from the FDA in January due to risks of low calcium levels in certain patients. AMGN shares dropped by 0.91% following the news.
April 30, 2024 | 3:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amgen Inc's settlement with Sandoz over denosumab biosimilars may impact its market share for bone disorder treatments but resolves ongoing litigation. The FDA's serious warning on Prolia also poses reputational risks.
The settlement potentially opens up competition for Amgen's bone disorder treatments, which could affect its market share and revenue. The recent FDA warning on Prolia adds to the challenges by potentially affecting its reputation and sales.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Sandoz AG's settlement with Amgen allows for the launch of its denosumab biosimilars, Jubbonti and Wyost, potentially increasing its market presence in the bone disorder treatment sector.
The settlement removes legal barriers for Sandoz, enabling it to enter the market with its biosimilars. This could significantly boost its position in the treatment of bone disorders, pending successful market introduction and adoption.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Sandoz AG's settlement with Amgen over denosumab biosimilars marks a positive development for its business, potentially enhancing its competitive stance in the biosimilar market.
Similar to SDZNY, the settlement with Amgen allows Sandoz to proceed with its biosimilar plans, likely benefiting its market share and financial performance in the biosimilar sector.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90